Everolimus and pazopanib (E/P) benefit genomically selected patients with metastatic urothelial carcinoma.
Saved in:
| Title: | Everolimus and pazopanib (E/P) benefit genomically selected patients with metastatic urothelial carcinoma. |
|---|---|
| Authors: | Bellmunt J; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. joaquim.bellmunt@gmail.com.; Htal Del Mar Research Institute-IMIM, Barcelona, Spain. joaquim.bellmunt@gmail.com., Lalani AA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Juravinski Cancer Centre, McMaster University, Hamilton, Canada., Jacobus S; Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA, USA., Wankowicz SA; The Eli and Edythe L. Broad Institute of Harvard and MIT, Cambridge, MA, USA., Polacek L; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Takeda DY; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Harshman LC; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Wagle N; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; The Eli and Edythe L. Broad Institute of Harvard and MIT, Cambridge, MA, USA., Moreno I; Fundación Jiménez Díaz University Hospital, Madrid, Spain., Lundgren K; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Bossé D; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Van Allen EM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; The Eli and Edythe L. Broad Institute of Harvard and MIT, Cambridge, MA, USA., Choueiri TK; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Rosenberg JE; Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA. |
| Source: | British journal of cancer [Br J Cancer] 2018 Sep; Vol. 119 (6), pp. 707-712. Date of Electronic Publication: 2018 Sep 17. |
| Publication Type: | Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Nature Publishing Group on behalf of Cancer Research UK Country of Publication: England NLM ID: 0370635 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-1827 (Electronic) Linking ISSN: 00070920 NLM ISO Abbreviation: Br J Cancer |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
